柯萨奇病毒A16型感染性模型 z-bio 2021-02-24 335

　　Objective: To establish a simple and reliable small rodent experimental animal model sensitive to Coxsackie virus A16 (CVA16).

　　Method: Choose gerbils of different ages, inoculate CVA16 intraperitoneally, observe for 14 days, and then select the most suitable age group that is sensitive to the virus. Next, compare and determine the relationship between the inoculation dose and the effect. Its 50% lethal dose (LD50); determine the titer of CVA16 virus in blood and major tissues and organs 3 days after infection. Finally, after two injections of Gerville with the CVA16 inactivated vaccine at the age of 1 and 11, he was infected with the LD50 dose of the virus on 14 days. Observe and record Gavill's weight, symptoms and mortality. After two weeks, blood was drawn from the eyes, and the titers of neutralizing antibodies and total antibody levels were measured. Through the micro-neutralization test and ELISA detection.

　　Result: After being infected with CVA16, gerbils showed clinical symptoms such as hyperactivity, weakness of hind limbs, paralysis and death. Gerbils of different ages are more likely to be infected with CVA16 and have different degrees of post-infection diseases. Gerbils that are 14 days old are more susceptible to infection, while gerbils that are 28 days old are less likely to be infected. The most sensitive and optimal vaccination age is 14 days. LD50 is 1x104.5 CCID50. Blood and major tissues and organs 3 days after infection. The 14-day-old snakes immunized with two injections of high-titer CVA16 virus inactivated vaccine were challenged with the LD50 dose, and the survival rate was 87.5%. The ratio of CVA16 neutralizing antibodies produced by the geometric mean (GMT) vine vaccine immunization was 28.14. The antibody was positive The rate is 87.5%.

　　Conclusion: Gerbils are sensitive to CVA16, and the virus can replicate and spread effectively in the body. It can be used as a reliable small animal model for studying the pathogenic mechanism of CVA16, vaccine development and drug evaluation.